MCM10 promotes hepatocellular carcinoma progression through cyclin D1 regulation

doi:10.4251/wjgo.119834

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 8

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Aug 15, 2026; 18(8): 119834
Published online Aug 15, 2026. doi: 10.4251/wjgo.119834

Table 1 Correlation of MCM10 protein expression with clinicopathological parameters, n (%)

Characteristics	All case	MCM10 expression		P value
Characteristics	All case	Low	High	P value
Cases	147	85	62
Age (years)				0.985
≤ 50	76 (51.7)	44 (51.8)	32 (51.6)
> 50	71 (48.3)	41 (48.2)	30 (48.4)
Gender				0.763
Male	129 (87.8)	74 (87.1)	55 (88.7)
Female	18 (12.2)	11 (12.9)	7 (11.3)
HBsAg				0.787
Negative	30 (20.4)	18 (21.2)	12 (19.4)
Positive	117 (79.6)	67 (78.8)	50 (80.6)
ALT (U/L)				0.779
≤ 40	81 (55.1)	46 (54.1)	35 (56.5)
> 40	66 (44.9)	39 (45.9)	27 (43.5)
TBil (μmol/L)				0.165
≤ 17.1	110 (74.8)	60 (70.6)	50 (80.6)
> 17.1	37 (25.2)	25 (29.4)	12 (19.4)
PT (s)				0.348
≤ 13.5	131 (89.1)	74 (87.1)	57 (91.9)
> 13.5	16 (10.9)	11 (12.9)	5 (8.1)
ALB (g/L)				0.885
≥ 35	137 (93.2)	79 (92.9)	58 (93.5)
< 35	10 (6.8)	6 (7.1)	4 (6.5)
AFP (ng/mL)				0.031
≤ 200	93 (63.3)	60 (70.6)	33 (53.2)
> 200	54 (36.7)	25 (29.4)	29 (46.8)
Capsule integrity				0.050
Complete	66 (44.9)	44 (51.8)	22 (35.5)
No/incomplete	81 (55.1)	41 (48.2)	40 (64.5)
Tumor number				0.635
Single	105 (71.4)	62 (72.9)	43 (69.4)
Multiple (≥ 2)	42 (28.6)	23 (27.1)	19 (30.6)
Tumor differentiation				0.889
I-II	82 (55.8)	47 (55.3)	35 (56.5)
III-IV	65 (44.2)	38 (44.7)	27 (43.5)
Tumor size				0.721
≤ 5 cm	57 (38.8)	34 (40.0)	23 (37.1)
> 5 cm	90 (61.2)	51 (60.0)	39 (62.9)
T stage				0.034
T1-T2	106 (72.1)	67 (78.8)	39 (62.9)
T3-T4	41 (27.9)	18 (21.2)	23 (37.1)
Vascular invasion				0.080
No	106 (72.1)	66 (71.8)	40 (72.6)
Yes	41 (27.9)	19 (28.2)	22 (27.4)
BCLC stage				0.280
A-B	102 (69.4)	56 (65.9)	46 (74.2)
C	45 (30.6)	29 (34.1)	16 (25.8)

Bold values indicate significant P < 0.05. ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; TBil: Total bilirubin; PT: Prothrombin time; ALB: Albumin; AFP: Alpha-fetoprotein; HBsAg: Hepatitis B surface antigen.

Full Size Table

Table 2 Stratified analysis of the association between MCM10 expression and overall survival of hepatocellular carcinoma

Variables	All case	MCM10^low		MCM10^high		HR (95%CI)¹	P value¹
Variables	All case	Case number	MST (months)	Case number	MST (months)	HR (95%CI)¹	P value¹
Cases	147	85	87.0	62	46.5	1.692 (1.015-2.819)	0.044
Age (years)
≤ 50	76	44	87.0	32	48.0	2.322 (1.105-4.880)	0.026
> 50	71	41	87.0	30	46.0	1.301 (0.636-2.661)	0.470
Gender
Male	129	74	89.0	55	51.0	1.682 (0.956-2.957)	0.071
Female	18	11	45.0	7	28.0	1.814 (0.549-5.996)	0.329
HBsAg
Negative	30	18	90.0	12	53.0	1.604 (0.607-4.241)	0.341
Positive	117	67	69.0	50	20.5	1.802 (0.987-3.291)	0.055
ALT (U/L)
≤ 40	81	46	88.0	35	44.0	2.002 (1.061-3.778)	0.032
> 40	66	39	85.0	27	57.0	1.220 (0.504-2.951)	0.659
TBIL (μmol/L)
≤ 17.1	110	60	86.0	50	46.5	1.551 (0.873-2.756)	0.135
> 17.1	37	25	89.0	12	46.0	0.604 (0.071-5.172)	0.646
PT (s)
≤ 13.5	131	74	89.0	57	51.0	1.635 (0.946-2.826)	0.078
> 13.5	16	11	79.0	5	10.0	4.397 (0.921-21.000)	0.063
ALB (g/L)
≥ 35	137	79	87.0	58	52.0	1.717 (1.004-2.936)	0.048
< 35	10	6	67.0	4	6.5	2.594 (0.354-18.991)	0.348
AFP (ng/mL)
≤ 200	93	60	89.5	33	53.0	1.425 (0.698-2.906)	0.331
> 200	54	25	67.0	29	28.0	1.745 (0.803-3.794)	0.160
Capsule integrity
Complete	66	44	100.0	22	81.5	1.094 (0.410-2.918)	0.857
No/incomplete	81	41	71.0	40	20.5	1.863 (1.006-3.452)	0.048
Tumor number
Single	105	62	96.0	43	55.0	1.646 (0.827-3.277)	0.156
Multiple (≥ 2)	42	23	58.0	19	23.0	1.752 (0.814-3.770)	0.151
Tumor differentiation
I-II	82	47	99.0	35	55.0	1.591 (0.742-3.412)	0.233
III-IV	65	38	73.5	27	28.0	1.751 (0.881-3.482)	0.110
Tumor size
≤ 5 cm	57	34	85.0	23	74.0	0.729 (0.256-2.077)	0.554
> 5 cm	90	51	89.0	39	20.0	2.383 (1.302-4.362)	0.005
T stage
T1-T2	106	67	85.0	39	62.0	1.454 (0.757-2.794)	0.261
T3-T4	41	18	101.5	23	21.0	1.729 (0.730-4.096)	0.213
Vascular invasion
No	106	66	86.0	40	60.5	1.393 (0.724-2.679)	0.321
Yes	41	19	89.0	22	20.0	2.130 (0.900-5.039)	0.085
BCLC stage
A-B	102	56	96.0	46	54.0	1.645 (0.851-3.179)	0.139
C	45	29	84.0	16	15.0	2.414 (1.060-5.497)	0.036

¹Hazard ratio and P value were derived from univariate analysis.

Bold values indicate significant P < 0.05. MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; ALT: Alanine aminotransferase; TBil: Total bilirubin; PT: Prothrombin time; ALB: Albumin; AFP: Alpha-fetoprotein; HBsAg: Hepatitis B surface antigen.

Full Size Table

Table 3 Stratified analysis on the association between MCM10⁺ Cyclin D1 expression and overall survival of hepatocellular carcinoma

Variables	All case	MCM10^low and Cyclin D1^low		MCM10^high or Cyclin D1^high		HR (95%CI)¹	P value¹
Variables	All case	Case number	MST (months)	Case number	MST (months)	HR (95%CI)¹	P value¹
Cases	147	48	100.0	99	53.0	2.426 (1.309-4.496)	0.005
Age (years)
≤ 50	76	31	89.0	45	53.0	1.838 (0.850-3.975)	0.122
> 50	71	17	110.0	54	55.0	4.167 (1.261-13.768)	0.019
Gender
Male	129	43	108.0	86	53.0	3.270 (1.579-6.771)	0.001
Female	18	5	27.0	13	45.0	0.474 (0.130-1.735)	0.260
HBsAg
Negative	30	10	62.5	20	34.5	1.647 (0.578-4.691)	0.350
Positive	117	38	106.5	79	55.0	2.932 (1.356-6.341)	0.006
ALT (U/L)
≤ 40	81	26	96.5	55	51.0	1.892 (0.919-3.894)	0.084
> 40	66	22	104.0	44	55.0	4.223 (1.238-14.401)	0.021
TBIL (μmol/L)
≤ 17.1	110	34	96.5	76	50.5	2.183 (1.083-4.401)	0.029
> 17.1	37	14	105.0	23	73.0	3.182 (0.864-11.722)	0.082
PT (s)
≤ 13.5	131	43	100.0	88	56.0	2.173 (1.138-4.150)	0.019
> 13.5	16	5	100.0	11	24.0	5.565 (0.664-46.619)	0.113
ALB (g/L)
≥ 35	137	46	96.5	91	57.0	2.083 (1.114-3.895)	0.022
< 35	10	2	116.0	8	10.0	58.055 (0.049-68429)	0.260
AFP (ng/mL)
≤ 200	93	35	100.0	58	72.0	1.495 (0.723-3.090)	0.278
> 200	54	13	110.0	41	36.0	6.531 (1.536-27.765)	0.011
Capsule integrity
Complete	66	24	100.0	42	91.5	1.211 (0.454-3.230)	0.701
No/incomplete	81	24	97.0	57	27.0	3.871 (1.693-8.852)	0.001
Tumor number
Single	105	38	106.5	67	72.0	1.954 (0.905-4.216)	0.088
Multiple (≥ 2)	42	10	69.0	32	27.5	2.841 (0.979-8.249)	0.055
Tumor differentiation
I-II	82	28	107.5	54	69.0	2.363 (0.951-5.873)	0.064
III-IV	65	20	87.0	45	36.0	2.373 (1.026-5.487)	0.043
Tumor size
≤ 5 cm	57	24	82.5	33	82.0	0.678 (0.261-1.760)	0.425
> 5 cm	90	24	110.0	66	35.0	5.575 (1.984-15.666)	0.001
T stage
T1-T2	106	43	100.0	63	76.0	1.518 (0.731-3.153)	0.263
T3-T4	41	5	100.0	36	19.0	3.776 (0.881-16.193)	0.074
Vascular invasion
No	106	41	100.0	65	67.0	2.059 (1.018-4.163)	0.044
Yes	41	7	110.0	34	26.0	2.875 (0.669-12.360)	0.156
BCLC stage
A-B	102	35	108.0	67	55.0	2.546 (1.155-5.609)	0.020
C	45	13	89.0	32	45.0	2.091 (0.779-5.613)	0.143

¹Hazard ratio and P value were derived from univariate analysis.

Full Size Table

Citation: Chen YR, Wang G, He LJ, Ye HW, Wang LF, Zou DD, Wang MQ, Xie HW, Zhu SL, Wang XY. MCM10 promotes hepatocellular carcinoma progression through cyclin D1 regulation. World J Gastrointest Oncol 2026; 18(8): 119834
URL: https://www.wjgnet.com/1948-5204/full/v18/i8/119834.htm
DOI: https://dx.doi.org/10.4251/wjgo.119834

Chen YR, Wang G, He LJ, Ye HW, Wang LF, Zou DD, Wang MQ, Xie HW, Zhu SL, Wang XY. MCM10 promotes hepatocellular carcinoma progression through cyclin D1 regulation. World J Gastrointest Oncol 2026; 18(8): 119834 [DOI: 10.4251/wjgo.119834]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.